Add-on nemolizumab beneficial in steroid-refractory atopic dermatitis

  • Silverberg JI & al.
  • J Allergy Clin Immunol
  • 23 Aug 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Add-on nemolizumab is associated with clinical benefit in patients with moderate to severe atopic dermatitis (AD) inadequately controlled with topical corticosteroids (TCS), according to data from a phase 2b randomised controlled trial.

Why this matters

  • Nemolizumab offers a novel mechanism for AD treatment and has already shown efficacy as monotherapy.

Study design

  • 226 patients with TCS-refractory moderate to severe AD and severe pruritus were assigned to receive nemolizumab (10, 30, or 90 mg; n=169) or placebo (n=57) in addition to TCS.
  • Funding: Nestlé Skin Health–Galderma R&D.

Key results

  • Nemolizumab 30 mg was associated with improved Eczema Area and Severity Index (EASI) compared with placebo at week 16 (P<.01 and week>
  • Nemolizumab 30 mg was associated with improved rates of >50% improvement in EASI (EASI-50) compared with placebo at week 16 (P=.016) and week 24 (P=.014).
  • Nemolizumab 30 mg was associated with improvements in peak pruritus numeric rating scale compared with placebo at week 16 (P≤.001) and week 24 (P≤.001).
  • Serious treatment-emergent adverse events were reported in 5.5% of patients receiving nemolizumab 10 mg, 3.5% of patients receiving nemolizumab 30 or 90 mg, and 1.8% of patients receiving placebo.

    Limitations

    • Relatively short follow-up.
    • Small sample size.

    Please confirm your acceptance

    To gain full access to GPnotebook please confirm:

    By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

    Submit